Article Trunk



Chemistry / M2 Pharma, “Trovagene Completes First Dosing Cohort of Patients in Ongoing Phase 1b/2 AML Trial.”

06.20.2018 · Posted in Uncategorized
M2 PHARMA-June 20, 2018-Trovagene Completes First Dosing Cohort of Patients in Ongoing Phase 1b/2 AML Trial (C)2018 M2 COMMUNICATIONS
  • San Diego, California-based molecular diagnostics company Trovagene, Inc. (NASDAQ: TROV) has completed the first dose cohort of PCM-075, a highly-selective oral polo-like kinase 1 Inhibitor, in combination with decitabine, in its phase 1b/2...

Leave a Reply

You must be logged in to post a comment.

%d bloggers like this: